Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan to See Grueling Battle for Free-Price Viagra Generics
August 20, 2014
- Launch of Daiichi Sankyo Espha’s Cravit Generics Not Yet Determined
August 20, 2014
- Daiichi Sankyo Starts PIII Study of Etanercept Biosimilar, Eying Approval in FY2016
August 20, 2014
- Approval Conditions Lifted for Tykerb: GSK
August 20, 2014
- Pfizer Reveals First Doctor Payments amid Delays in Disclosure
August 19, 2014
- Eisai Licenses Pariet Successor to Zeria
August 19, 2014
- Eisai Files for Regulatory Approval of Lenvatinib in US, Europe
August 19, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
August 18, 2014
- Genzyme Japan Appoints Former Bausch & Lomb Japan President Ashikaga as Its New President
August 18, 2014
- Teva Receives Marketing Authorization for 4 APIs/9 Products
August 18, 2014
- Santen Files NDA for Cosopt Mini for Glaucoma and Ocular Hypertension
August 18, 2014
- GSK Seeks Japan Regulatory Approval for Colistin
August 14, 2014
- Ethical Drug Sales Edge 0.4% Higher in June: Crecon Report
August 14, 2014
- Matsumotokiyoshi Holdings to Transfer OTC Drug-Related Wholesale Business to Alfresa Healthcare
August 14, 2014
- Japan Pharma Market Loses Ground in April-June, Nexium Joins Top 10 List: IMS
August 12, 2014
- PIII Study of Halaven for Advanced NSCLC Fails to Improve OS: Eisai
August 12, 2014
- US FDA Approves Velcade Retreatment in Patients with Multiple Myeloma: Takeda
August 12, 2014
- Astellas Ties Up with Cancer Research UK for Joint Research for Cancer Treatments
August 12, 2014
- Asahi Kasei Pharma Aims to Achieve Sales Target of 100 Billion Yen in FY2015 Despite Debut of Flivas Generics: President
August 11, 2014
- University of Tokyo, Fujitsu, Kowa Discover Novel Anticancer Drug Candidate through IT-Based Drug Discovery Technology
August 11, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…